Products billed under this code include Istodax lyophilized, Romidepsin lyophilized.
Payment limit per 0.1 MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Istodax lyophilized | Celgene Corporation | 59572-0984-01 | 100 | $3,234.30 |
| Romidepsin lyophilized | FreseniUS Kabi USA, LLC | 63323-0926-88 | 100 | $3,234.30 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $32.343 | +$1.63 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted September 17, 2026 |
| 3Q26 | $30.713 | −$0.083 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted September 15, 2026 |
| 2Q26 | $30.796 | −$0.11 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted September 15, 2026 |
| 1Q26 | $30.906 | +$0.129 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted September 15, 2026 |
| 4Q25 | $30.777 | −$0.298 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted September 8, 2026 |
| 3Q25 | $31.075 | −$0.466 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted March 10, 2026 |
| 2Q25 | $31.541 | +$1.149 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted March 10, 2026 |
| 1Q25 | $30.392 | +$0.529 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted December 19, 2025 |
| 4Q24 | $29.863 | +$0.089 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 11, 2025 |
| 3Q24 | $29.774 | −$0.775 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 11, 2025 |
| 2Q24 | $30.549 | −$1.412 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted March 11, 2025 |
| 1Q24 | $31.961 | +$1.302 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted December 19, 2024 |
| 4Q23 | $30.659 | +$0.289 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted October 10, 2024 |
| 3Q23 | $30.37 | −$1.118 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 5, 2024 |
| 2Q23 | $31.488 | −$0.669 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted February 23, 2024 |
| 1Q23 | $32.157 | −$0.63 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted December 6, 2023 |
| 4Q22 | $32.787 | −$0.441 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 22, 2023 |
| 3Q22 | $33.228 | $0.00 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 9, 2023 |
| 2Q22 | $33.228 | $0.00 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted December 14, 2022 |
| 1Q22 | $33.228 | −$0.45 | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 8, 2022 |
| 4Q21 | $33.678 | – | 0.1 MG | Inj romidepsin lyophil 0.1mg | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
